Pfizer Reports Top-Line Results from Phase 3 Trial of Lyrica Capsules CV in Patients with Inadequately Treated Painful Diabetic Peripheral Neuropathy

Pfizer announced that a Phase 3 randomized withdrawal design study for Lyrica in patients with inadequately treated painful diabetic peripheral neuropathy did not meet its primary efficacy endpoint.  READ MORE

Source: Marketwatch

Send this to a friend